Form 4: Amgen Director Charles Holley Acquires 665 Shares

Amgen Inc. Director Charles M. Holley acquired 665 shares of common stock through the vesting of Restricted Stock Units.

Summary

• Director Charles M. Holley acquired 665 shares of Amgen Inc. common stock on May 19, 2026.
• The acquisition resulted from the immediate vesting of Restricted Stock Units (RSUs) granted under the 2009 Director Incentive Program.
• Following this transaction, the director's direct beneficial ownership increased to 12,799.0331 shares.
• The director maintains an additional indirect holding of 1,260 shares through the Holley Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Director maintains a significant equity stake in the company, aligning interests with shareholders.
• The transaction reflects standard equity-based compensation for board members.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that this filing represents routine director compensation within the biotechnology sector, where equity-based incentives are standard practice to ensure board alignment with long-term corporate performance.

Comparison to Industry Standards

• The use of Restricted Stock Units for director compensation is consistent with standard corporate governance practices among large-cap pharmaceutical and biotechnology firms like Pfizer, Gilead, and AbbVie.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• None identified.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Trading, Director Compensation, Equity Incentive Plan